Clinicopathological features | Total | MED12 mutations | Without MED12 mutations | p Value |
---|---|---|---|---|
Age (years; median 43, IQR 32–52 years) | 0.332 | |||
<Mean age | 52 | 35 (67.3%) | 17 (32.7%) | |
≥Mean age | 60 | 35 (58.3%) | 25 (41.7%) | |
Ethnicity | 0.372 | |||
Chinese | 75 | 46 (61.3%) | 29 (38.7%) | |
Malay | 9 | 4 (44.4%) | 5 (55.6%) | |
Indian | 3 | 2 (66.7%) | 1 (33.3%) | |
Others | 25 | 18 (72.0%) | 7 (28.0%) | |
Grade | 0.217 | |||
Benign | 66 | 43 (65.1%) | 23 (34.9%) | |
Borderline | 32 | 21 (65.6%) | 11 (34.4%) | |
Malignant | 14 | 6 (42.8%) | 8 (57.2%) | |
Size (mm; median 40, IQR 27–60 mm) | 0.322 | |||
<Mean size | 68 | 45 (43.8%) | 23 (56.2%) | |
≥Mean size | 44 | 25 (56.8%) | 19 (43.2%) | |
Microscopic borders | 0.553 | |||
Circumscribed | 81 | 52 (64.2%) | 29 (35.8%) | |
Permeative | 31 | 18 (58.1%) | 13 (41.9%) | |
Stromal hypercellularity | 0.570 | |||
Mild | 41 | 26 (63.4%) | 15 (36.6%) | |
Moderate | 59 | 38 (64.4%) | 21 (35.6%) | |
Marked | 12 | 6 (50.0%) | 6 (50.0%) | |
Stromal atypia | 0.234 | |||
Mild | 78 | 53 (67.9%) | 25 (32.1%) | |
Moderate | 25 | 11 (44.0%) | 14 (56.0%) | |
Marked | 9 | 6 (66.7%) | 3 (33.3%) | |
Stromal overgrowth | 0.191 | |||
Absent | 92 | 58 (63.0%) | 34 (37.0%) | |
Present | 20 | 12 (60.0%) | 8 (40.0%) | |
Mitotic activity/10 HPFs | 0.775 | |||
0–4 | 64 | 40 (62.5%) | 24 (37.5%) | |
5–9 | 29 | 17 (58.6%) | 12 (41.4%) | |
≥10 | 19 | 13 (68.4%) | 6 (31.6%) |
HPF, high power field.